vs
Side-by-side financial comparison of Protalix BioTherapeutics, Inc. (PLX) and SES AI Corp (SES). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $4.6M, roughly 2.0× SES AI Corp). Protalix BioTherapeutics, Inc. runs the higher net margin — -60.3% vs -373.5%, a 313.1% gap on every dollar of revenue. Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-11.1M).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
SES S.A. is a Luxembourgish communications satellite operator supplying video and data connectivity worldwide to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions.
PLX vs SES — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.1M | $4.6M |
| Net Profit | $-5.5M | $-17.0M |
| Gross Margin | 49.4% | 11.3% |
| Operating Margin | -51.1% | -387.7% |
| Net Margin | -60.3% | -373.5% |
| Revenue YoY | -49.9% | — |
| Net Profit YoY | -184.8% | 50.7% |
| EPS (diluted) | $-0.06 | $-0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.1M | $4.6M | ||
| Q3 25 | $17.9M | $7.1M | ||
| Q2 25 | $15.7M | $3.5M | ||
| Q1 25 | $10.1M | $5.8M | ||
| Q4 24 | $18.2M | — | ||
| Q3 24 | $18.0M | — | ||
| Q2 24 | $13.5M | — | ||
| Q4 23 | $10.5M | — |
| Q4 25 | $-5.5M | $-17.0M | ||
| Q3 25 | $2.4M | $-20.9M | ||
| Q2 25 | $164.0K | $-22.7M | ||
| Q1 25 | $-3.6M | $-12.4M | ||
| Q4 24 | $6.5M | — | ||
| Q3 24 | $3.2M | — | ||
| Q2 24 | $-2.2M | — | ||
| Q4 23 | $-6.0M | — |
| Q4 25 | 49.4% | 11.3% | ||
| Q3 25 | 53.4% | 51.1% | ||
| Q2 25 | 62.5% | 73.7% | ||
| Q1 25 | 19.1% | 78.7% | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 53.4% | — | ||
| Q2 24 | 29.8% | — | ||
| Q4 23 | 15.5% | — |
| Q4 25 | -51.1% | -387.7% | ||
| Q3 25 | 11.9% | -262.0% | ||
| Q2 25 | 7.5% | -652.3% | ||
| Q1 25 | -41.0% | -401.7% | ||
| Q4 24 | 39.6% | — | ||
| Q3 24 | 22.2% | — | ||
| Q2 24 | -18.0% | — | ||
| Q4 23 | -53.5% | — |
| Q4 25 | -60.3% | -373.5% | ||
| Q3 25 | 13.2% | -293.9% | ||
| Q2 25 | 1.0% | -642.2% | ||
| Q1 25 | -35.8% | -214.6% | ||
| Q4 24 | 35.6% | — | ||
| Q3 24 | 18.0% | — | ||
| Q2 24 | -16.4% | — | ||
| Q4 23 | -57.6% | — |
| Q4 25 | $-0.06 | $-0.05 | ||
| Q3 25 | $0.03 | $-0.06 | ||
| Q2 25 | $0.00 | $-0.07 | ||
| Q1 25 | $-0.05 | $-0.04 | ||
| Q4 24 | $0.10 | — | ||
| Q3 24 | $0.03 | — | ||
| Q2 24 | $-0.03 | — | ||
| Q4 23 | $-0.03 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $14.7M | $29.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $48.2M | $214.8M |
| Total Assets | $82.3M | $272.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $14.7M | $29.5M | ||
| Q3 25 | $13.6M | $35.3M | ||
| Q2 25 | $17.9M | $11.8M | ||
| Q1 25 | $19.5M | $56.1M | ||
| Q4 24 | $19.8M | — | ||
| Q3 24 | $27.4M | — | ||
| Q2 24 | $23.4M | — | ||
| Q4 23 | $23.6M | — |
| Q4 25 | $48.2M | $214.8M | ||
| Q3 25 | $52.9M | $228.2M | ||
| Q2 25 | $49.9M | $249.2M | ||
| Q1 25 | $45.2M | $269.9M | ||
| Q4 24 | $43.2M | — | ||
| Q3 24 | $32.4M | — | ||
| Q2 24 | $28.6M | — | ||
| Q4 23 | $33.6M | — |
| Q4 25 | $82.3M | $272.6M | ||
| Q3 25 | $82.3M | $288.8M | ||
| Q2 25 | $78.5M | $290.5M | ||
| Q1 25 | $73.9M | $306.0M | ||
| Q4 24 | $73.4M | — | ||
| Q3 24 | $61.6M | — | ||
| Q2 24 | $91.5M | — | ||
| Q4 23 | $84.4M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.0M | $-10.4M |
| Free Cash FlowOCF − Capex | $1.6M | $-11.1M |
| FCF MarginFCF / Revenue | 17.8% | -243.7% |
| Capex IntensityCapex / Revenue | 4.4% | 15.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-13.6M | $-61.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.0M | $-10.4M | ||
| Q3 25 | $-3.7M | $-14.3M | ||
| Q2 25 | $-5.2M | $-10.8M | ||
| Q1 25 | $-5.1M | $-22.8M | ||
| Q4 24 | $4.0M | — | ||
| Q3 24 | $4.1M | — | ||
| Q2 24 | $-3.6M | — | ||
| Q4 23 | $3.6M | — |
| Q4 25 | $1.6M | $-11.1M | ||
| Q3 25 | $-4.2M | $-14.7M | ||
| Q2 25 | $-5.7M | $-11.6M | ||
| Q1 25 | $-5.4M | $-23.7M | ||
| Q4 24 | $3.6M | — | ||
| Q3 24 | $4.0M | — | ||
| Q2 24 | $-3.8M | — | ||
| Q4 23 | $3.3M | — |
| Q4 25 | 17.8% | -243.7% | ||
| Q3 25 | -23.7% | -206.9% | ||
| Q2 25 | -36.2% | -329.6% | ||
| Q1 25 | -53.0% | -410.0% | ||
| Q4 24 | 19.6% | — | ||
| Q3 24 | 22.4% | — | ||
| Q2 24 | -28.1% | — | ||
| Q4 23 | 31.9% | — |
| Q4 25 | 4.4% | 15.6% | ||
| Q3 25 | 2.8% | 6.0% | ||
| Q2 25 | 2.8% | 22.8% | ||
| Q1 25 | 3.0% | 15.8% | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 1.3% | — | ||
| Q4 23 | 2.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | -1.58× | — | ||
| Q2 25 | -31.91× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.61× | — | ||
| Q3 24 | 1.27× | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
SES
Segment breakdown not available.
